T. Ruthsatz

Preclinical Evaluation of a Replication-Deficient Intranasal ΔNS1 H5N1 Influenza Vaccine

J. Oxford, A. Mann, B. Ferko, 2009, PloS one.

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

D. Voss, J. Humer, T. Muster, 2009, Vaccine.

Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

F. Horling, B. Dietrich, F. Scheiflinger, 2016, Journal of thrombosis and haemostasis : JTH.

Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence

G. Kato, M. Pelzing, G. Vercellotti, 2022, Journal of clinical medicine.

Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey

B. Majer, M. Schuster, F. Scheiflinger, 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys

F. Horling, B. Reipert, M. Schuster, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.

B. Ferko, T. Muster, M. Wolschek, 2011, Vaccine.

Single HA2 Mutation Increases the Infectivity and Immunogenicity of a Live Attenuated H5N1 Intranasal Influenza Vaccine Candidate Lacking NS1

J. Humer, B. Ferko, T. Muster, 2011, PloS one.

Creatine improves health and survival of mice

D. Rujescu, H. Fuchs, M. Angelis, 2008, Neurobiology of Aging.

Creatine improves health and survival in mice

D. Rujescu, H. Fuchs, M. H. Angelis, 2007 .